Where is Editas Medicine headquartered?

Editas Medicine is located in Cambridge, MA.

Who invested in Editas Medicine?

Editas Medicine has 13 investors including Geekdom Fund And Geekdom Fund.

How much funding has Editas Medicine raised to date?

Editas Medicine has raised ____.

When was the last funding round for Editas Medicine?

Editas Medicine closed its lastf unding roundon Jul 19, 2017 from a Convertible Note round.

Company Information
Company Timeline (Coming Soon)

editasmedicine.com

Editas Medicine

Editas Medicine is a Massachusetts-based biotechnology company that develops and commercializes gene-edited therapeutics for the treatment of ocular diseases and cancer.

Business Model:

Revenue: $25.6M

Employees: 201-500

Geographic Data

Address: 11 Hurley Street

City: Cambridge

State: MA

Zip: 02141

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$231M

Raised Total:

$473M

Social

Facebook

Twitter

Crunchbase

Metrics

1,649,160Website Global Rank

14,499Website Monthly Traffic

Twitter Followers

Description

Editas Medicine is a Massachusetts-based biotechnology company that develops and commercializes gene-edited therapeutics for the treatment of ocular diseases and cancer.

Contact Phone:
+16174019000

Contact Email:

IPO Details

Editas Medicine went public on 2/3/2016 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
2/3/2016

IPO Valuation:
$571M

Ticker Symbol:
EDIT

IPO Price:
$16/share

Amount Raised:
$94M

Live

Opened: -/share

EBITDA	-
Total Cash	-
Total Debt	-
Total Revenue	-
Total Profit (Gross)	-
PE Ratio	-

Investments

Announced Date	Company	Transaction	Money Raised

Funding Rounds

Announced Date	Transaction	Number of Investors	Money Raised	Lead Investors
11/2013	Series A	4	$43M	Flagship Pioneering Polaris Partners Third Rock Ventures Partners Innovation Fund Flagship Pioneering Polaris Partners Third Rock Ventures
8/2015	Series B		$0	Khosla Ventures Omega Funds Boris Nikolic Third Rock Ventures Jennison Associates Polaris Partners GV EcoR1 Capital Fidelity Management and Research Company T. Rowe Price Boris Nikolic Viking Global Investors Innova Capital Flagship Pioneering Khosla Ventures Omega Funds Boris Nikolic Third Rock Ventures Jennison Associates Polaris Partners GV EcoR1 Capital Fidelity Management and Research Company T. Rowe Price Boris Nikolic Viking Global Investors Innova Capital Flagship Pioneering
2/2016	IPO		$94.4M
6/2020	Post-IPO Equity		$215.6M
8/2015	Series B		$120M	Deerfield Management Viking Global Investors LP Flagship Ventures Polaris Partners Third Rock Ventures
5/2015	Funding Round		$0	Juno Therapeutics Juno Therapeutics
1/2021	Post-IPO Equity		$231M
8/2015	Series B	15	$120M	Khosla Ventures Omega Funds Boris Nikolic Third Rock Ventures Jennison Associates Polaris Partners GV EcoR1 Capital Fidelity Management and Research Company T. Rowe Price Boris Nikolic Khosla Ventures Omega Funds Boris Nikolic Third Rock Ventures Jennison Associates Polaris Partners GV EcoR1 Capital Fidelity Management and Research Company T. Rowe Price Boris Nikolic
5/2015	Funding Round	1	$47M	Juno Therapeutics Juno Therapeutics

Acquisitions

Announced Date	Name	Price

Employee Demographics

Employee Departments

Employee States

Similar Companies

Uniview Singapore VEID	Revenue: 0 - 100000 Employees: Industry: Software	Details
Konkuk University Medical Center	Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education	Details
Daemon Technologies	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain	Details
Ace International Trade	Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial	Details
An Hòa Communications	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising	Details